[go: up one dir, main page]

CL2018003060A1 - Compuestos de pirimidina como inhibidores de la quinasa jak. - Google Patents

Compuestos de pirimidina como inhibidores de la quinasa jak.

Info

Publication number
CL2018003060A1
CL2018003060A1 CL2018003060A CL2018003060A CL2018003060A1 CL 2018003060 A1 CL2018003060 A1 CL 2018003060A1 CL 2018003060 A CL2018003060 A CL 2018003060A CL 2018003060 A CL2018003060 A CL 2018003060A CL 2018003060 A1 CL2018003060 A1 CL 2018003060A1
Authority
CL
Chile
Prior art keywords
inhibitors
compounds
pyrimidine compounds
jak kinase
intermediaries
Prior art date
Application number
CL2018003060A
Other languages
English (en)
Inventor
Ryan Hudson
Jennifer Kozak
Paul R Fatheree
Dante D Podesto
Melissa Fleury
Anne-Marie Beausoleil
Xiaojun Huang
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CL2018003060A1 publication Critical patent/CL2018003060A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCIÓN PROVEE COMPUESTOS DE FÓRMULA (I), DONDE LAS VARIABLES SE DEFINEN EN LA MEMORIA DESCRIPTIVA, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LOS MISMOS, QUE SON INHIBIDORES DE LAS QUINASAS JAK. LA INVENCIÓN TAMBIÉN PROVEE COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES COMPUESTOS, MÉTODOS DE USO DE TALES COMPUESTOS PARA TRATAR ENFERMEDADES GASTROINTESTINALES Y OTRAS ENFERMEDADES INFLAMATORIAS, Y PROCESOS E INTERMEDIARIOS ÚTILES PARA PREPARAR TALES COMPUESTOS.
CL2018003060A 2016-04-28 2018-10-26 Compuestos de pirimidina como inhibidores de la quinasa jak. CL2018003060A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662328737P 2016-04-28 2016-04-28

Publications (1)

Publication Number Publication Date
CL2018003060A1 true CL2018003060A1 (es) 2018-12-14

Family

ID=58672793

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003060A CL2018003060A1 (es) 2016-04-28 2018-10-26 Compuestos de pirimidina como inhibidores de la quinasa jak.

Country Status (20)

Country Link
US (3) US10028960B2 (es)
EP (1) EP3433253B1 (es)
JP (1) JP6881879B2 (es)
KR (1) KR102244257B1 (es)
CN (1) CN109071529B (es)
AU (1) AU2017258186B2 (es)
BR (1) BR112018072168A2 (es)
CA (1) CA3020506A1 (es)
CL (1) CL2018003060A1 (es)
CO (1) CO2018011408A2 (es)
DK (1) DK3433253T3 (es)
EA (1) EA035226B1 (es)
ES (1) ES2779880T3 (es)
IL (1) IL262386B (es)
MX (1) MX377180B (es)
PT (1) PT3433253T (es)
SG (1) SG11201809342YA (es)
TW (1) TWI726094B (es)
WO (1) WO2017189822A1 (es)
ZA (1) ZA201807179B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX378963B (es) 2015-05-28 2025-03-10 Theravance Biopharma R&D Ip Llc Compuestos de naftiridina como inhibidores de quinasa jak.
ES2864035T3 (es) 2015-11-03 2021-10-13 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus
US10556901B2 (en) 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
US10028960B2 (en) * 2016-04-28 2018-07-24 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as JAK kinase inhibitors
EA202091016A1 (ru) 2017-10-27 2020-07-17 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Пиримидиновое соединение в качестве ингибитора jak киназы
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
WO2020108516A1 (zh) * 2018-11-27 2020-06-04 江苏豪森药业集团有限公司 含氮杂芳类衍生物调节剂、其制备方法和应用
MX2021006283A (es) * 2018-11-30 2021-10-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
ES2994097T3 (en) * 2019-04-24 2025-01-17 Theravance Biopharma R&D Ip Llc Pyrimidine jak inhibitors for the treatment of skin diseases
JP7470713B2 (ja) * 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
WO2021231272A1 (en) * 2020-05-14 2021-11-18 Theravance Biopharma R&D Ip, Llc Administration of gut-selective jak3 inhibitor
CN116368134A (zh) * 2020-10-09 2023-06-30 施万生物制药研发Ip有限责任公司 制备泛jak抑制剂的方法和相关中间体化合物
CN116390922B (zh) * 2020-10-21 2025-07-18 珠海联邦制药股份有限公司 硒杂环类化合物及其应用
WO2023011359A1 (zh) * 2021-08-05 2023-02-09 南京明德新药研发有限公司 桥环类化合物及其应用
CN113883920B (zh) * 2021-10-25 2024-01-23 安徽华铂再生资源科技有限公司 一种降低空分装置空冷塔出口温度的方法
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用
WO2025040148A1 (zh) * 2023-08-22 2025-02-27 北京普祺医药科技股份有限公司 一种用于jak抑制剂的外用凝胶及其用途
WO2025059417A1 (en) * 2023-09-15 2025-03-20 Morphic Therapeutic, Inc. INHIBITING HUMAN INTEGRIN α4β7

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2432222C (en) 2000-12-21 2008-07-29 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2006074057A2 (en) * 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
CN101360740A (zh) 2005-11-16 2009-02-04 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶
UY30444A1 (es) 2006-06-30 2008-01-31 Astrazeneca Ab Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
WO2008005538A2 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
KR20140103972A (ko) 2011-12-22 2014-08-27 에프. 호프만-라 로슈 아게 세린/트레오닌 키나아제 억제제로서의 2,4-다이아민-피리미딘 유도체
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (es) * 2014-08-21 2018-03-31
MX378963B (es) 2015-05-28 2025-03-10 Theravance Biopharma R&D Ip Llc Compuestos de naftiridina como inhibidores de quinasa jak.
US10028960B2 (en) 2016-04-28 2018-07-24 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as JAK kinase inhibitors

Also Published As

Publication number Publication date
ZA201807179B (en) 2019-08-28
CO2018011408A2 (es) 2018-11-13
JP2019514903A (ja) 2019-06-06
EA035226B1 (ru) 2020-05-19
US20180303836A1 (en) 2018-10-25
WO2017189822A1 (en) 2017-11-02
US11110095B2 (en) 2021-09-07
IL262386A (en) 2018-11-29
KR102244257B1 (ko) 2021-04-26
TWI726094B (zh) 2021-05-01
SG11201809342YA (en) 2018-11-29
CA3020506A1 (en) 2017-11-02
IL262386B (en) 2021-08-31
TW201739747A (zh) 2017-11-16
AU2017258186B2 (en) 2020-09-17
KR20190002591A (ko) 2019-01-08
MX377180B (es) 2025-03-07
PT3433253T (pt) 2020-04-30
US10485803B2 (en) 2019-11-26
US10028960B2 (en) 2018-07-24
CN109071529B (zh) 2021-08-06
EA201892436A1 (ru) 2019-04-30
AU2017258186A1 (en) 2018-11-15
EP3433253B1 (en) 2020-02-12
EP3433253A1 (en) 2019-01-30
US20170312280A1 (en) 2017-11-02
CN109071529A (zh) 2018-12-21
MX2018013191A (es) 2019-02-13
BR112018072168A2 (pt) 2019-02-12
ES2779880T3 (es) 2020-08-20
JP6881879B2 (ja) 2021-06-02
DK3433253T3 (da) 2020-04-06
US20200046709A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
CL2018003060A1 (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
CL2017002994A1 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CL2020000283A1 (es) Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak.
CL2018001145A1 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
EA202090291A2 (ru) Производные бипиразола в качестве ингибиторов jak
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
MX376947B (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CR20170309A (es) Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas
MX371312B (es) Pirazolil-ureas como inhibidores de quinasas.
EA201890827A1 (ru) Конденсированные производные пиразола в качестве ингибиторов киназы
CL2018000611A1 (es) Sales de un inhibidor de pim quinasa
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов
EA202192822A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores